Zellweger syndrome is a rare, inherited disorder in which the body’s cells cannot build functional peroxisomes, tiny structures inside cells that break down fats and perform other critical chemical reactions. Without working peroxisomes, toxic fatty acids accumulate in the brain, liver, and kidneys while essential fats the body needs for brain development and vision go unproduced. The condition affects an estimated 1 in 50,000 newborns in the United States, with much lower rates reported in Japan (roughly 1 in 500,000).
How Peroxisome Failure Affects the Body
Every cell in your body contains peroxisomes, small compartments packed with more than 50 enzymes responsible for breaking down and building important fats. Their most critical jobs include breaking down very long chain fatty acids (VLCFA), processing a branched fat called phytanic acid, and manufacturing plasmalogens, a type of fat essential for brain development and bone growth.
When peroxisomes don’t form properly, the consequences cascade through multiple systems. Very long chain fatty acids pile up in tissues, directly damaging the brain, nerves, and adrenal glands. At the same time, the body can’t produce enough of the omega-3 fat DHA, which is vital for brain function and vision. Plasmalogen deficiency disrupts skeletal development, contributes to cataracts, and impairs growth and intellectual development. The liver takes damage from the buildup of bile acid precursors. Kidney stones can form from excess oxalate. And because peroxisomes normally help neutralize hydrogen peroxide (a corrosive byproduct of cell metabolism), their absence means cells suffer increased oxidative damage. Cholesterol levels also tend to run low, likely because peroxisome dysfunction triggers chronic stress in the cell’s protein-processing machinery.
The Zellweger Spectrum
Zellweger syndrome is the most severe form of a broader condition now called Zellweger spectrum disorder (ZSD). Historically, doctors described three separate diagnoses: Zellweger syndrome at the severe end, neonatal adrenoleukodystrophy in the middle, and infantile Refsum disease as the mildest form. Today, because all three share the same underlying genetic cause and exist on a continuum, clinicians prefer the terms severe, intermediate, and milder ZSD.
Severe ZSD (classic Zellweger syndrome) typically appears at birth. Infants show profound muscle weakness, characteristic facial features, brain malformations, seizures, inability to feed, kidney cysts, and liver dysfunction. These babies are significantly impaired from the start and usually die within the first year of life, often having made no developmental progress.
Intermediate and milder forms may not be obvious at birth. Children often come to medical attention later because of developmental delays, hearing loss, or vision problems. Liver dysfunction can cause bleeding issues, and some children have presented in their first year with intracranial bleeding. The course varies widely: many of these children learn to walk and talk, but hearing and vision typically worsen over time. Some develop progressive destruction of the brain’s white matter (leukodystrophy), leading to loss of skills they had previously gained.
Signs and Symptoms
In the severe form, the signs are usually apparent immediately after birth. Newborns have extremely low muscle tone, reduced movement, and a weak cry. Feeding is a major struggle from the start, and seizures can begin in the first days of life.
Distinctive facial features are a hallmark: a high forehead, a flattened face, a broad nasal bridge, widely spaced eyes, and unusually large soft spots between the skull bones. Eye problems include cataracts, glaucoma, abnormal eye movements (nystagmus), and retinal damage. Hearing loss ranges from partial to profound.
Organ involvement is extensive. An enlarged liver occurs in about 80% of cases, and kidney cysts appear in roughly 70%. Adrenal glands may fail to produce enough hormones, a condition called adrenal insufficiency. Skeletal abnormalities show up on X-rays as distinctive bright spots in the cartilage near joints. Tooth enamel abnormalities are also common.
In older children, adolescents, or adults with milder forms, the picture looks different. They may present with developmental delays, worsening coordination and balance (cerebellar ataxia), nerve damage in the hands and feet, or progressive loss of previously acquired abilities.
Genetic Cause
ZSD is caused by mutations in PEX genes, which provide instructions for building peroxisomes. More than a dozen different PEX genes have been linked to the disorder. The condition follows an autosomal recessive inheritance pattern, meaning a child must inherit a faulty copy of the same PEX gene from each parent to develop it. Parents who each carry one copy are typically unaffected.
The specific PEX gene involved and the nature of the mutations influence where a child falls on the spectrum. Mutations that completely eliminate peroxisome formation tend to cause the severe form, while mutations that allow some residual peroxisome function often result in intermediate or milder disease. The degree of very long chain fatty acid buildup in the blood correlates with clinical severity.
How It’s Diagnosed
The first step in diagnosis is typically a blood test measuring very long chain fatty acids. In all patients with severe ZSD, VLCFA levels are elevated. Doctors look at the level of a specific 26-carbon fatty acid and its ratios to shorter-chain fatty acids. Blood levels of phytanic acid and pipecolic acid (a biomarker for peroxisome dysfunction) can provide additional evidence.
Zellweger spectrum disorder is now included in newborn screening programs in parts of the United States. The screening uses the same heel-prick blood spot collected from all newborns, measuring VLCFA levels. If results are out of range, the baby’s healthcare team follows up with confirmatory testing. Newborn screening can flag the disorder but cannot determine which form of ZSD a baby has.
Genetic testing to identify the specific PEX gene mutation confirms the diagnosis and can help with family planning for future pregnancies.
Management and Outlook
There is no cure for Zellweger spectrum disorder, and treatment focuses on managing symptoms and supporting quality of life. For infants with the severe form, this centers on feeding support (often through a tube), seizure management, and monitoring liver and kidney function. The prognosis for severe ZSD is poor: most infants do not survive beyond their first year.
For children with intermediate or milder forms, the approach is broader and more sustained. Hearing aids or cochlear implants may address progressive hearing loss. Vision is monitored and managed as problems develop. Physical and occupational therapy help maintain mobility and daily functioning for as long as possible. Liver function, adrenal hormone levels, and vitamin K status require ongoing monitoring, since liver dysfunction can cause dangerous bleeding episodes. Some children receive dietary modifications, including supplementation with DHA to partially compensate for what their bodies cannot produce.
The course for milder forms is highly variable. Some individuals survive into adolescence or adulthood, though the progressive nature of the disorder means that hearing, vision, and neurological function typically decline over time. Families often work with teams of specialists spanning neurology, hepatology, ophthalmology, audiology, and genetics to coordinate care across these many systems.